Eli Lilly and Vanda Pharmaceuticals secured FDA approval for Nereus (tradipitant). The drug is indicated for the prevention of vomiting induced by motion.
This approval marks the first new drug for motion sickness in more than 40 years. The FDA based its decision on positive results from three pivotal clinical trials, which demonstrated a significant reduction in vomiting and featured a favorable safety profile.
Vanda Pharmaceuticals' stock surged approximately 21% in pre-market trading following the announcement. Vanda licensed tradipitant from Eli Lilly in 2012 and plans to launch the therapy in the coming months.
The drug is also being developed for other indications. These include nausea and vomiting induced by GLP-1 agonists.